Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HanAll Biopolymer
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
HanAll Biopharma is a Korean biopharmaceutical company developing biologics and small molecules for immune‑mediated and inflammatory eye diseases; its lead anti‑FcRn antibody HL161 (batoclimab) has completed multiple Phase 2 studies in autoimmune indications through global partners, while additional ophthalmology and immunology assets are in early‑ to mid‑stage development.[1][3]
- Therapeutic areas
- HematologyImmunologyEndocrinologyNeurologyRheumatologyOphthalmology
- Modalities
- Monoclonal antibodyBiologicSmall molecule
- Industry
- Biotech
02
Partnerships
Daewoong PharmaceuticalHarbour BioMedRoivant SciencesTurn BiotechNautilus Biotech (acquired)
Beyond the preview
Go deeper on HanAll Biopolymer.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HanAll Biopolymer.